Videos

Sandip M. Prasad, MD, MPhil, details key findings from the phase 3 ENVISION trial, which supported the approval of mitomycin intravesical solution in LG-IR-NMIBC.

An expert summarizes that although it is currently too early to determine optimal sequencing among bladder cancer therapies, emerging strategies involving combination treatments and immune system priming show promise for enhancing efficacy, particularly in high-risk patients, underscoring the need for further research to guide personalized treatment decisions.

An expert summarizes that Tara-002 offers a familiar, intravesical administration and manageable adverse effect profile similar to BCG, making it a safer and more easily adoptable option compared with systemic immunotherapies, especially important for preserving bladder function and quality of life in heavily treated BCG-unresponsive patients.

Suzanne B. Merrill, MD, FACS, unpacks key findings from the CREST trial and outlines data of interest from the POTOMAC and PATAPSCO trials, which are set to read out later this year.

Jack Andrews, MD; Alicia Morgans, MD, MPH; and Ashley Ross MD, PhD, discuss how trial design, inclusion criteria, and end points like radiographic progression-free survival vs overall survival impact clinical decision-making in prostate cancer treatment, emphasizing the importance of quality of life data and the shift from using ADT alone as standard care toward combination therapies in prostate cancer management.

Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES, emphasizes a careful, individualized approach to managing bladder and bowel symptoms in women with a history of disordered eating.

Jennifer A. Robles, MD, MPH, outlines 3 key factors that may be preventing more widespread adoption of HoLEP across the US.

Panelists discuss how UGN-102, a reverse thermal hydrogel formulation of mitomycin, offers an FDA-approved ablative treatment option for patients with intermediate-risk non-muscle invasive bladder cancer (NMIBC), demonstrating 80% complete response rates in the ENVISION trial (NCT05243550) and allowing for the de-escalation of surveillance and reduced surgical burden.

Urologists from the University of North Carolina share insights into key advancements across the field of urologic oncology.

Timothy D. McClure outlines his approach to patient selection with focal therapy as well as how NanoKnife fits into that landscape.

Panelists discuss how shared decision-making allows patients to test-drive oral androgen deprivation therapy options, providing flexibility for those concerned about quality-of-life impact or performance status, enabling them to start or stop treatment as needed.

Panelists discuss how patient preference plays a significant role in androgen deprivation therapy selection, with most patients preferring oral agents that offer rapid onset and quick testosterone recovery when treatment is stopped.

Sandip M. Prasad, MD, MPhil, shares his thoughts on the impact of the FDA approval of mitomycin for intravesical solution for patients with LG-IR-NMIBC.

Jennifer A. Robles, MD, MPH, highlights potential factors contributing to the surge in HoLEP utilization across the US.

Suzanne B. Merrill, MD, FACS explains the challenges with BCG monotherapy and the emergence of novel regimens combining BCG with ICIs in high-risk NMIBC.

Timothy D. McClure, MD, discusses focal therapy with IRE, specifically highlighting its benefits and limitations compared with other treatment options.

Policy availability varied by specialty, with urology leading in program-specific policies—yet still only at 11%.

Jansen underscores the need for urologists to go beyond symptom treatment and focus on identifying root causes of testosterone deficiency.

Aleece Fosnight, MSPAS, PA-C, emphasizes that any patient presenting with urinary incontinence or related symptoms should be evaluated for pelvic floor dysfunction.

Jack Andrews, MD; Alicia Morgans, MD, MPH; and Ashley Ross MD, PhD, discuss how trial design, inclusion criteria, and end points like radiographic progression-free survival vs overall survival impact clinical decision-making in prostate cancer treatment, emphasizing the importance of quality of life data and the shift from using ADT alone as standard care toward combination therapies in prostate cancer management.

Panelists discuss how clinicians can confidently adapt to newer androgen deprivation therapy options like relugolix in combination therapies despite limited prospective data, emphasizing that oral agents simplify patient visits and provide equivalent testosterone suppression.

Panelists discuss how NCCN guidelines provide a framework for selecting appropriate androgen deprivation therapy (ADT) regimens across different disease states, with combination therapies now being standard of care rather than ADT monotherapy in most cases.

Findlay advocated for comprehensive patient counseling that includes the full range of BMS options, not just those available within a provider’s immediate practice.

Jennifer A. Robles, MD, MPH, discusses a study assessing trends and geographic disparities in HoLEP utilization across the United States.

On the urinary side, Fosnight prioritizes pelvic floor physical therapy as a first-line intervention for incontinence, citing evidence of significant symptom improvement.

Robert Jansen, MD, emphasizes that all TRT delivery methods can be effective, but selection depends on patient preference, insurance coverage, and individual response.

Joseph Song, MD, details his experience using the CVAC device for SURE procedures.

Sonam Saxena highlights a study on factors that may predict failure of robotic ureteroplasty with buccal mucosa graft.

An expert would summarize that interpreting bladder cancer clinical trial data requires careful consideration of varying trial designs, definitions of treatment failure, and diagnostic methods, as differences from real-world practice can limit the direct applicability and comparison of results.

An expert summarizes that the emerging concept of broad immune potentiation—exemplified by therapies like Terra-002—seeks to activate multiple immune pathways for a more durable antitumor response in bladder cancer, offering a promising shift from traditional, narrowly targeted treatments and paving the way for more personalized and effective care.